Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
12:04:25 EDT Mon 06 May 2024
Enter Symbol
or Name
USA
CA



News for U:BMY from 2023-05-07 to 2024-05-06 - 139 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2024-05-06 06:59U:BMYNews ReleaseEuropean Medicines Agency Validates Bristol Myers Squibb's Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) for the First-Line Treatment of Adult Patients with Microsatellite...
2024-05-01 08:00U:BMYNews ReleaseEditas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
2024-04-29 06:00U:BMYNews ReleaseRepertoire(TM) Immune Medicines and Bristol Myers Squibb Announce Multi-Year Strategic Collaboration to Develop Tolerizing Vaccines for Autoimmune Diseases
2024-04-26 06:59U:BMYNews ReleaseCHMP Adopts Positive Opinion Recommending Approval of Bristol Myers Squibb's Opdivo(TM) (nivolumab) in Combination with Cisplatin and Gemcitabine for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-04-25 06:59U:BMYNews ReleaseBristol Myers Squibb Reports First Quarter Financial Results for 2024
2024-04-22 06:59U:BMYNews ReleaseBristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
2024-04-11 09:11U:BMYNews ReleaseBuilding a Better Future: Bristol Myers Squibb 2023 ESG Report
2024-04-08 11:30U:BMYNews ReleaseKRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
2024-04-08 07:03U:BMYNews ReleaseBristol Myers Squibb Releases 2023 ESG Report Demonstrating Progress and Setting New Long-Term Goals
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Interim Long-Term Efficacy Data from the EMERGENT-4 Trial Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-06 13:15U:BMYNews ReleaseBristol Myers Squibb Presents New Pooled Interim Long-Term Safety and Metabolic Outcomes Data from the EMERGENT Program Evaluating KarXT in Schizophrenia at the 2024 Annual Congress of the Schizophrenia International Research Society
2024-04-05 09:05U:BMYNews ReleaseU.S. FDA Approves Bristol Myers Squibb and 2seventy bio's Abecma for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma After Two Prior Lines of Therapy
2024-04-02 20:08U:BMYNews ReleaseEuropean Commission Expands Approval of Bristol Myers Squibb's Reblozyl(TM) (luspatercept) to Include First-Line Treatment of Transfusion-Dependent Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (LR-MDS)
2024-04-02 14:32U:BMYNews ReleaseBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2024-04-02 06:59U:BMYNews ReleaseBristol Myers Squibb Releases 2023 Environmental, Social and Governance Report Demonstrating Progress and Setting New Long-Term Goals
2024-03-29 09:46U:BMYNews ReleaseBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
2024-03-28 16:05U:BMYNews ReleaseBristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung...
2024-03-28 16:01U:BMYNews ReleaseBristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn's Disease
2024-03-28 07:30U:BMYNews ReleasePerspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
2024-03-26 06:59U:BMYNews ReleaseBristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
2024-03-25 08:00U:BMYNews ReleaseBristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
2024-03-20 16:45U:BMYNews ReleaseBristol Myers Squibb's Abecma (idecabtagene vicleucel) Becomes First CAR T Cell Therapy Approved in the European Union in Earlier Lines for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
2024-03-20 06:59U:BMYNews ReleaseBristol Myers Squibb Announces CheckMate -9DW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Meets Primary Endpoint of Overall Survival for the First-Line Treatment of Advanced Hepatocellular Carcinoma
2024-03-19 06:59U:BMYNews ReleaseBristol Myers Squibb and Ted Danson Empower Those with Plaque Psoriasis to Take Action in "SO, Have You Found It?" Campaign
2024-03-18 08:44U:BMYNews ReleaseBristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
2024-03-15 18:27U:BMYNews ReleaseFDA Advisory Committee Votes in Favor of Bristol Myers Squibb's and 2seventy bio's Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
2024-03-14 21:35U:BMYNews ReleaseU.S. FDA Approves Bristol Myers Squibb's Breyanzi(TM) as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2024-03-11 16:16U:BMYNews ReleaseBristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
2024-03-07 14:23U:BMYNews ReleaseU.S. Food and Drug Administration Approves Opdivo(TM) (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2024-03-06 16:17U:BMYNews ReleaseBristol Myers Squibb to Participate in Upcoming Investor Conferences
2024-03-01 16:16U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2024-02-29 06:59U:BMYNews ReleaseBristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
2024-02-26 16:16U:BMYNews ReleaseBristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
2024-02-26 08:35U:BMYNews ReleaseBristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
2024-02-23 06:59U:BMYNews ReleaseBristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl(TM) (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
2024-02-23 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
2024-02-20 06:59U:BMYNews ReleaseU.S. Food and Drug Administration (FDA) Accepts Supplemental New Drug Application for KRAZATI ‚ ® (adagrasib) in Combination with Cetuximab as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or...
2024-02-14 19:57U:BMYNews ReleaseBristol Myers Squibb Prices $13 Billion of Senior Unsecured Notes
2024-02-14 16:16U:BMYNews ReleaseBristol Myers Squibb Recommends Stockholders Reject ¢ € œMini-Tender ¢ €  Offer by Tutanota LLC
2024-02-14 08:30U:BMYNews ReleaseAnal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
2024-02-14 06:59U:BMYNews ReleaseU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb ¢ € ™s Application for Augtyro ¢ „ ¢ (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors
2024-02-12 06:59U:BMYNews ReleaseBristol Myers Squibb and RayzeBio Announce Expiration of HSR Act Waiting Period
2024-02-07 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Acceptance of U.S. and EU Regulatory Filings for Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Surgery and Adjuvant Opdivo in Resectable Non-Small Cell Lung Cancer
2024-02-05 09:22U:BMYNews ReleaseBristol Myers Squibb Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC
2024-02-05 09:00U:BMYNews ReleaseBristol Myers Squibb Named One of America ¢ € ™s Most JUST Companies by JUST Capital and CNBC
2024-02-05 06:59U:BMYNews ReleaseBristol Myers Squibb and 2seventy bio Share Update on U.S. FDA Oncologic Drugs Advisory Committee Meeting for Abecma in Triple-Class Exposed Multiple Myeloma Based on KarMMa-3 Study
2024-02-02 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2023
2024-01-30 06:59U:BMYNews ReleaseRegulatory Applications Accepted in the U.S. and Japan for Bristol Myers Squibb ¢ € ™s Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma (FL) and Relapsed or Refractory Mantle Cell Lymphoma (MCL)
2024-01-27 10:00U:BMYNews ReleaseSubcutaneous Nivolumab (nivolumab and hyaluronidase) Shows Noninferiority Compared to Intravenous Opdivo (nivolumab) in Advanced or Metastatic Clear Cell Renal Cell Carcinoma in CheckMate -67T Trial
2024-01-26 07:13U:BMYNews ReleaseBristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma
2024-01-23 08:30U:BMYNews ReleaseBristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
2024-01-22 17:05U:BMYNews ReleaseEight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
2024-01-22 17:00U:BMYNews ReleaseOpdivo ‚ ® (nivolumab) in Combination with CABOMETYX ‚ ® (cabozantinib) Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma
2024-01-20 10:00U:BMYNews ReleaseOpdivo (nivolumab) Plus Yervoy (ipilimumab) Reduced the Risk of Disease Progression or Death by 79% Versus Chemotherapy in Patients with Microsatellite Instability-High or Mismatch Repair Deficient Metastatic Colorectal Cancer in CheckMate -8HW Trial
2024-01-17 06:59U:BMYNews ReleaseBristol Myers Squibb Data at ASCO GU 2024 Showcase Transformative Research in the Treatment of Genitourinary Cancers
2024-01-02 06:59U:BMYNews ReleaseEuropean Medicines Agency Validates Bristol Myers Squibb ¢ € ™s Application for Repotrectinib for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer and NTRK-Positive Solid Tumors
2023-12-26 07:13U:BMYNews ReleaseBristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
2023-12-26 06:59U:BMYNews Release ‚  Bristol Myers Squibb Adds Premier Radiopharmaceutical Platform with Acquisition of RayzeBio
2023-12-22 07:05U:BMYNews ReleaseBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
2023-12-22 06:59U:BMYNews ReleaseBristol Myers Squibb Strengthens Neuroscience Portfolio with Acquisition of Karuna Therapeutics
2023-12-22 06:59U:BMYNews ReleaseBristol Myers Squibb to Present at J.P. Morgan ¢ € ™s 42nd Annual Healthcare Conference
2023-12-20 16:16U:BMYNews ReleaseBristol Myers Squibb to Participate in the 2024 Goldman Sachs Healthcare C-Suite Unscripted Conference
2023-12-15 16:54U:BMYNews ReleaseBristol Myers Squibb Provides Update on RELATIVITY-123 Trial Evaluating the Fixed-Dose Combination of Nivolumab and Relatlimab in Patients with Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer
2023-12-15 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Fourth Quarter 2023 on February 2, 2024
2023-12-14 07:00U:BMYNews ReleaseTerray Therapeutics Announces Multi-Target Collaboration with Bristol Myers Squibb
2023-12-11 21:00U:BMYNews ReleaseTwo Early Studies Evaluating Potential First-in-Class CELMoD ¢ „ ¢ Agent Golcadomide for the Treatment of Non-Hodgkin Lymphomas Presented at ASH 2023
2023-12-11 20:30U:BMYNews ReleaseBristol Myers Squibb Announces Data at ASH 2023 from Diverse Multiple Myeloma Pipeline, Underscoring Range of Tailored Treatment Approaches to Address Unique Patient Needs
2023-12-11 19:30U:BMYNews ReleaseAbecma Delivers Sustained Progression-Free Survival Versus Standard Regimens in Earlier Lines of Therapy for Relapsed and Refractory Multiple Myeloma Based on Longer-Term Follow-up from KarMMa-3
2023-12-11 16:15U:BMYNews ReleaseSystImmune and Bristol Myers Squibb Announce a Global Strategic Collaboration Agreement for the Development and Commercialization of BL-B01D1
2023-12-10 21:26U:BMYNews ReleaseBristol Myers Squibb Presents New Data at ASH 2023 Demonstrating Clinical Benefit Across B-cell Malignancies with Breyanzi as a Second-Line Treatment in High-Risk Follicular Lymphoma and in Relapsed or Refractory Chronic Lymphocytic Leukemia
2023-12-09 17:00U:BMYNews ReleaseBristol Myers Squibb Presents Primary Efficacy and Safety Analysis of the Phase 3 COMMANDS Trial of Reblozyl for Treatment of Anemia in Erythropoiesis Stimulating Agent-Na ƒ ¯ve Patients with Lower-Risk Myelodysplastic Syndromes at ASH 2023
2023-12-07 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Phase 3 CheckMate -8HW Trial Evaluating Opdivo (nivolumab) Plus Yervoy (ipilimumab) Compared to Chemotherapy in Microsatellite Instability ¢ € “High or Mismatch Repair Deficient Metastatic Colorectal Cancer Meets Primary...
2023-12-07 06:30U:BMYNews ReleaseBristol Myers Squibb Announces Additional $3 Billion Share Repurchase Authorization
2023-12-06 16:16U:BMYNews ReleaseBristol Myers Squibb Announces Dividend Increase
2023-12-05 06:59U:BMYNews ReleaseU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb ¢ € ™s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic...
2023-11-28 06:30U:BMYNews ReleaseAvidity Biosciences Announces Expansion of Cardiovascular Collaboration with Bristol Myers Squibb for up to Five Targets Utilizing Avidity's Proprietary AOC ¢ „ ¢ Platform Technology
2023-11-20 06:59U:BMYNews ReleaseBristol Myers Squibb and 2seventy bio Provide Update on U.S. FDA Review of sBLA for Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed or Refractory Multiple Myeloma
2023-11-17 10:46U:BMYNews ReleaseHow Is BMS Making Progress on Its Renewable Energy Goals?
2023-11-15 19:20U:BMYNews ReleaseU.S. Food and Drug Administration Approves Augtyro ¢ „ ¢ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer (NSCLC)
2023-11-09 16:18U:BMYNews ReleaseBristol Myers Squibb to Participate in the 2023 Jefferies London Healthcare Conference
2023-11-09 10:14U:BMYNews ReleaseU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb ¢ € ™s Application for Breyanzi (lisocabtagene maraleucel) for Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
2023-11-06 06:59U:BMYNews ReleaseBristol Myers Squibb to Present Data from Innovative Cardiovascular Portfolio at the American Heart Association Scientific Sessions 2023
2023-11-02 11:34U:BMYNews ReleaseBristol Myers Squibb ¢ € ™s First Disclosures and New Data at ASH 2023 Highlight Company ¢ € ™s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology
2023-11-02 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in the 2023 UBS BioPharma Conference
2023-10-31 18:25U:BMYNews ReleaseBristol Myers Squibb Appoints Christopher Boerner, Ph.D., to Chair of the Board of Directors, Effective April 1, 2024
2023-10-30 20:19U:BMYNews ReleaseBristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes
2023-10-30 08:00U:BMYNews ReleaseKaryopharm Announces Clinical Trial Collaboration with Bristol Myers Squibb to Evaluate Novel CELMoD ¢ „ ¢ Agent CC- 92480 Mezigdomide in Combination with Selinexor in Patients with Relapsed/Refractory Multiple Myeloma
2023-10-30 06:59U:BMYNews ReleaseEuropean Medicines Agency Validates Bristol Myers Squibb ¢ € ™s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
2023-10-26 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Third Quarter Financial Results for 2023
2023-10-24 06:59U:BMYNews ReleaseBristol Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for Investigational LPA1 Antagonist for Progressive Pulmonary Fibrosis
2023-10-19 06:59U:BMYNews ReleasePhase 3 CheckMate -67T Trial of Subcutaneous Nivolumab (nivolumab and hyaluronidase) Meets Co-Primary Endpoints in Advanced or Metastatic Clear Cell Renal Cell Carcinoma
2023-10-18 16:15U:BMYNews ReleaseThe Robert A. Winn Diversity in Clinical Trials Award Announces Third Group of Physicians in Program to Increase Diversity in Clinical Trials
2023-10-17 15:51U:BMYNews ReleaseNeoadjuvant Opdivo (nivolumab) with Chemotherapy Provides Benefits for Patients with Resectable Non-Small Cell Lung Cancer Across PD-L1 Expression Levels with Three-Year Follow Up in CheckMate -816 Trial
2023-10-17 15:48U:BMYNews ReleaseOpdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial
2023-10-17 15:23U:BMYNews ReleasePerioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Shows Significant Improvement in Event-Free Survival for Patients with Resectable Non-Small Cell Lung Cancer in Phase 3 CheckMate -77T Trial
2023-10-13 21:18U:BMYNews ReleaseU.S. Food and Drug Administration Approves Opdivo ‚ ® (nivolumab) as Adjuvant Treatment for Eligible Patients with Completely Resected Stage IIB or Stage IIC Melanoma1
2023-10-12 07:15U:BMYNews ReleaseBristol Myers Squibb to Showcase Data Demonstrating Improved Outcomes in Earlier Stages of Cancer, Durable Long-Term Benefits with Opdivo-Based Regimens, and Addressing High Unmet Needs in Multiple Tumor Types at ESMO 2023
2023-10-11 18:01U:BMYNews ReleaseSotyktu (deucravacitinib) Long-Term Data Demonstrate Durable Efficacy and Consistent Safety for up to Three Years in Moderate-to-Severe Plaque Psoriasis
2023-10-11 02:01U:BMYNews ReleaseBristol Myers Squibb Presents New Zeposia (ozanimod) Data on Long-Term Disease Progression and Cognition in Patients with Relapsing Forms of Multiple Sclerosis
2023-10-08 17:16U:BMYNews ReleaseBristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics
2023-10-06 06:30U:BMYNews ReleaseParadigm and Bristol Myers Squibb collaborate to build a new model for clinical trials
2023-09-26 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Third Quarter 2023 on October 26, 2023
2023-09-22 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Perioperative Regimen of Neoadjuvant Opdivo (nivolumab) and Chemotherapy Followed by Adjuvant Opdivo Significantly Improves Event-Free Survival in Patients with Resectable Non-Small Cell Lung Cancer
2023-09-20 06:59U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2023-09-17 19:57U:BMYNews ReleaseSamsung Biologics announces expanded strategic agreement with Bristol Myers Squibb to manufacture an antibody cancer drug substance
2023-09-14 08:30U:BMYNews ReleaseBristol Myers Squibb Highlights Advancing Pipeline and Differentiated Research Platforms to Support Long-Term Sustainable Growth at R&D Day
2023-09-11 06:59U:BMYNews ReleaseSix-Year Outcomes from Phase 3 CheckMate -227 Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) in the First-Line Treatment of Patients with Metastatic Non-Small Cell Lung Cancer
2023-09-07 07:00U:BMYNews ReleaseBristol Myers Squibb Celebrates a Decade of Its Coast 2 Coast 4 Cancer Cross-Country Bike Ride in Support of the V Foundation for Cancer Research
2023-09-01 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
2023-08-28 11:26U:BMYNews ReleaseLong-Term Follow-Up Data from Two Phase 3 Studies of CAMZYOS ‚ ® (mavacamten) Demonstrate Consistent and Durable Response in Patients with Symptomatic Obstructive Hypertrophic Cardiomyopathy (HCM)
2023-08-28 08:00U:BMYNews ReleaseCellares Announces Bristol Myers Squibb has Joined Technology Adoption Partnership Program to Evaluate Automated Manufacturing of CAR-T Cell Therapy on the Cell Shuttle Platform
2023-08-23 07:55U:BMYNews ReleaseBristol Myers Squibb Shares Progress Toward Its Environmental, Social, and Governance Initiatives and Its Health Equity Commitments
2023-08-22 16:18U:BMYNews ReleaseBristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma ‚  
2023-08-21 06:59U:BMYNews ReleaseBristol Myers Squibb to Showcase Data Across its Innovative Cardiovascular Portfolio at the European Society of Cardiology Congress 2023
2023-08-16 10:19U:BMYNews ReleaseUpdated Data from TRIDENT-1 Trial Show Durable Efficacy Benefits with Repotrectinib for Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023-08-10 06:59U:BMYNews ReleaseBristol Myers Squibb Enters Into $4 Billion Aggregate Accelerated Share Repurchase Agreements
2023-08-08 06:59U:BMYNews ReleaseBristol Myers Squibb Launches Clear Understanding Campaign to Reveal the Plain Truth About Living with Moderate to Severe Plaque Psoriasis
2023-07-27 06:59U:BMYNews ReleaseBristol Myers Squibb Reports Second Quarter Financial Results for 2023
2023-07-21 06:59U:BMYNews ReleaseBristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) as an Adjuvant Treatment for Patients with Completely Resected Stage IIB or IIC Melanoma
2023-07-12 06:59U:BMYNews ReleaseBristol Myers Squibb Launches Supporting You with UC, with Women ¢ € ™s World Cup Commentator, Former Professional Soccer Player and Ulcerative Colitis Patient, Rosie White
2023-07-10 16:01U:BMYNews ReleaseArbutus Appoints Two New Executives
2023-06-29 06:59U:BMYNews ReleaseBristol Myers Squibb Receives European Commission Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expression ¢ ‰ ¥1%
2023-06-28 08:00U:BMYNews ReleaseK36 Therapeutics Announces $70 Million Series B Financing to Fund Clinical Proof of Concept of KTX-1001, First-in-class Inhibitor of MMSET for Treatment of Multiple Myeloma Patients with Genetic Translocation (4;14)
2023-06-17 05:30U:BMYNews ReleaseBristol Myers Squibb ¢ € ™s Breyanzi (lisocabtagene maraleucel) Delivers Deep and Durable Responses in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma in TRANSCEND Clinical Trials Presented at ICML 2023
2023-06-15 20:23U:BMYNews ReleaseU.S. Food and Drug Administration Approves Addition of Positive Data from Phase 3 VALOR-HCM Study to CAMZYOS ‚ ® (mavacamten) Label
2023-06-14 16:16U:BMYNews ReleaseBristol Myers Squibb Announces Dividend
2023-06-08 16:16U:BMYNews ReleaseBristol Myers Squibb Receives U.S. FDA Approval of New State-of-the-Art Cell Therapy Manufacturing Facility in Devens, Massachusetts
2023-06-08 06:59U:BMYNews ReleaseBristol Myers Squibb to Report Results for Second Quarter 2023 on July 27, 2023
2023-06-04 08:00U:BMYNews ReleaseFour-Year Outcomes from Phase 3 CheckMate -9LA Trial Show Durable, Long-Term Survival with Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy for Patients with Metastatic Non-Small Cell Lung Cancer
2023-06-01 06:59U:BMYNews ReleaseBristol Myers Squibb to Participate in Upcoming Investor Conferences
2023-05-31 06:59U:BMYNews ReleaseBristol Myers Squibb to Hold R&D Day on September 14
2023-05-30 09:24U:BMYNews ReleaseBristol Myers Squibb to Present Late-Breaking Data for Breyanzi (lisocabtagene maraleucel) in Relapsed or Refractory Follicular Lymphoma and Mantle Cell Lymphoma at 2023 International Conference on Malignant Lymphoma
2023-05-30 06:59U:BMYNews ReleaseU.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb ¢ € ™s Application for Repotrectinib for the Treatment of Patients with Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer
2023-05-26 08:10U:BMYNews ReleaseBristol Myers Squibb Receives Positive CHMP Opinion Recommending Approval for Opdivo (nivolumab) with Chemotherapy as Neoadjuvant Treatment of Resectable Non-Small Cell Lung Cancer at High Risk of Recurrence in Patients with Tumor Cell PD-L1 Expre...
2023-05-25 17:05U:BMYNews ReleaseBristol Myers Squibb ¢ € ™s Breyanzi (lisocabtagene maraleucel) is First and Only CAR T to Deliver Deep and Durable Efficacy in Pivotal Multicenter Trial in Relapsed or Refractory Chronic Lymphocytic Leukemia, Based on Data Presented at ASCO 2023
2023-05-25 17:00U:BMYNews ReleaseBristol Myers Squibb to Present First Results at ASCO and EHA from Phase 3 COMMANDS Study of Reblozyl ‚ ® (luspatercept-aamt) in First-Line Treatment of Anemia in Adults with Lower-Risk Myelodysplastic Syndromes (MDS)
2023-05-25 06:59U:BMYNews ReleaseMilvexian Granted U.S. FDA Fast Track Designation for All Three Indications Under Evaluation in Phase 3 Librexia Program: Ischemic Stroke, Acute Coronary Syndrome and Atrial Fibrillation
2023-05-22 11:01U:BMYNews ReleaseBristol Myers Squibb ¢ € ™s Investigational LPA1 Antagonist Reduces the Rate of Lung Function Decline in Patients with Idiopathic Pulmonary Fibrosis
2023-05-11 13:41U:BMYNews ReleaseBristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023